PFIZER INC. for PFIZER INC.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 20, 2011 | $3,790,000 | Replaced |
| 1st Quarter - Amendment (this page) | May 18, 2012 | $3,850,000 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Trans Pacific Partnership Negotiations US - EU Dialogues (TEC) - market access and regulatory issues Japan Market Access and Regulatory Issues US-Korea Free Trade Agreement Russia market access (no bills) Israel Patent Issues (no bills) APEC Life Sciences Innovation Forum Brazil IP Thailand Compulsory Licensing India IP and Market Access issues Australian FTA Implementation Special 301 Reform Legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH DAMOND | — |
Taxation/Internal Revenue Code TAX
Repatriation Deferral Deferral for active-financing income- extension S. 1203 - R& D Tax Credit Extension and Enhancement H.R. 422 - R&D Tax Credit Extension and Enhancement H.R. 2098 - CFC Look Through Extension
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARIA CINO | — |
| KEN W COLE | — |
| ANTHONY PRINCIPI | — |
Copyright/Patent/Trademark CPT
Counterfeit Pharmaceuticals Expert Patent Courts Pilot Programs Patent Settlements Patent Reform Act, 2011 Protecting Consumer Access to Generic Drugs S.23 - America Invents Act, 2011 S. 27 - Preserve Access to Affordable Generics H.R. 1249 - America Invents Act, 2011
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEN W COLE | — |
| JENNIFER DUCK | — |
| MARY BRIDGET WALSH New | Deputy Legislative Director and Counsel |
| JENNIFER SWENSON WALTON New | — |
Health Issues HCR
Health Care Reform Comparative Effectiveness Research Prescription Drug User Fee Act (PDUFA) Follow on Biologics Medicare Part D Antibiotic Incentives Tax Extenders Antimicrobial Resistance Strategies to Address Antimicrobial Resistance H.R. 965 The Preservation of Antibiotics for Medical Treatment Act, 2011 H.R. 979 FEHBP Priscription Drug Integrity, Transparency and Cost Savings Act, 2011 H.R. 452 Medicare Decision Accountability Act, 2011 S. 668 Health Care Bureacrats Elimination Act, 2011
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEN W COLE | — |
| JENNIFER DUCK | — |
| JOHN PAUL HALLIWELL | — |
| MARY BRIDGET WALSH New | Deputy Legislative Director and Counsel |
| JENNIFER SWENSON WALTON New | — |
Consumer Issues/Safety/Products CSP
Importation The Food, Drug and Cosmetic Globalization Act Dextromethorphan Distribution Dextromethorphan Abuse Reduction H.R. 741 - Act to Prohibit the Marketing of Authorized Generic Drugs, 2011 S. 373 - Fair Prescription Drug Competition Act, 2011
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN PAUL HALLIWELL | — |
| JENNIFER SWENSON WALTON New | — |
Medicare/Medicaid MMM
Medicare Prescription Drug Benefit Medicaid Rebates Medicare Coverage Average Manufacturer Price Regulation Patient Protection and Affordable Care Act Implementation
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER DUCK | — |
| JOHN PAUL HALLIWELL | — |
| JENNIFER SWENSON WALTON New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.